Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Treasury Shares (2022 - 2025)

Historic Treasury Shares for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q3 2025 value amounting to $2.8 million.

  • Amylyx Pharmaceuticals' Treasury Shares rose 2164.98% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 2164.98%. This contributed to the annual value of $2.2 million for FY2024, which is 9890.53% up from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Treasury Shares of $2.8 million as of Q3 2025, which was up 2164.98% from $3.1 million recorded in Q2 2025.
  • Over the past 5 years, Amylyx Pharmaceuticals' Treasury Shares peaked at $3.2 million during Q1 2025, and registered a low of $596709.0 during Q1 2022.
  • Its 4-year average for Treasury Shares is $1.7 million, with a median of $1.1 million in 2023.
  • In the last 5 years, Amylyx Pharmaceuticals' Treasury Shares skyrocketed by 17407.95% in 2024 and then soared by 786.36% in 2025.
  • Quarter analysis of 4 years shows Amylyx Pharmaceuticals' Treasury Shares stood at $740297.0 in 2022, then skyrocketed by 50.28% to $1.1 million in 2023, then skyrocketed by 98.91% to $2.2 million in 2024, then grew by 24.66% to $2.8 million in 2025.
  • Its Treasury Shares stands at $2.8 million for Q3 2025, versus $3.1 million for Q2 2025 and $3.2 million for Q1 2025.